SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Biohaven Presents Three Posters on Graves’ Disease at ATA Meeting

Biohaven said it presented three posters at the 2026 American Thyroid Association meeting. The headline also says a Phase 3 pivotal trial of BHV-1300 is underway.

BHVN

Story updates

12:32:50 PM UTC
SquawkNews
Biohaven said its pivotal Phase 3 trial of BHV-1300 in Graves' disease is actively enrolling, with m

Related stories